Game-Changing Breast Cancer Drug Offers New Hope for Patients
Capivasertib, a new drug developed with UK expertise, has been approved by NHS in England for advanced breast cancer patients with specific genetic mutations. This targeted therapy, combined with hormone treatment, significantly extends progression-free survival and shrinks tumors in nearly a quarter of patients. Urgent genetic testing is essential to identify eligible patients, with appeals for Scotland to approve the drug.
Read More